BridgeBio Oncology Marc Cobo, Principal Accounting Officer, Receives Awards

What Happened

• Marc Cobo, Principal Accounting Officer of BridgeBio Oncology (BBOT), received 9,038 shares pursuant to the vesting/settlement of restricted stock units (RSUs) (acquired at $0.00). To cover tax withholding on that vesting, 203 shares were surrendered/withheld (disposed) at $5.52 each for a total withholding value of $1,121. In addition, he was granted a 43,700-share derivative award (acquired at $0.00) that vests on a multi-year schedule.

Key Details

• Transaction dates: reported period 2026-09-10; Form 4 filed 2026-09-14 (filed on the second business day after the transaction).
• Reported prices/values: RSU/derivative awards shown at $0.00 acquisition price; tax-withheld shares disposed at $5.52 each for $1,121 total.
• Transaction codes on the filing: A = grant/award (9,038 shares and 43,700 derivative), F = tax withholding (203 shares disposed).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes: F1 = RSUs (contingent right to 1 share each) vesting in 16 equal quarterly installments over four years starting April 21, 2026; F2 = 203 shares withheld to satisfy tax withholding on RSU vesting; F3 = the derivative award vests 1/48th monthly beginning April 21, 2026 (typical 4-year monthly schedule).

Context

• The activity is primarily awards/vesting (not an open-market purchase or sale); the only disposition was share withholding to cover taxes on vested RSUs (common administrative action, not a market-sale signal).
• The 43,700-share entry is a derivative award with monthly vesting (1/48th) — these are not immediately tradable shares until they vest and are settled.
• Filing appears timely based on the reported transaction date (9/10/2026) and the Form 4 filing date (9/14/2026).